NeuraLight

AI-driven Platform for Digitizing Neurology

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in February 2021 by Gil Shklarski, Micha Breakstone, and Edmund Benami, NeuraLight operates with 11–50 employees. The company has raised $30.5M across 2 funding rounds from 9 investors. In May 2022, NeuraLight secured Series A funding, with Koch Disruptive Technologies participating as a lead investor.

Business overview

NeuraLight is developing an AI-driven platform to enhance drug development, monitoring, and care for patients with neurological disorders. The company's core technology automatically extracts micro-oculometrics using standard smartphones or webcams, providing objective digital markers for neurological conditions. This solution aims to serve as a robust proxy for existing endpoints and establish a new measurement standard for precision medicine in neurology. NeuraLight focuses on transforming patient evaluation and care by digitizing neurological assessments, serving the healthcare and life sciences sectors, particularly pharmaceutical companies and healthcare providers.

Strategic signal

In April 2023, NeuraLight introduced a new assessment tool for ALS based on abnormal eye movements. This development signals the company's progress in leveraging AI and computer vision to create non-invasive, objective diagnostic methods for complex neurological diseases, potentially accelerating clinical trials and improving patient management in the neurology market.

Company Intelligence Q&A

What is NeuraLight's primary focus?
NeuraLight is focused on transforming the lives of people impacted by neurological disorders by digitizing patient evaluation and care, aiming to prevent, diagnose, and treat these conditions effectively.
When did NeuraLight secure its Series A funding?
In May 2022, NeuraLight secured Series A funding, with Koch Disruptive Technologies participating as a lead investor.
What was a key development for NeuraLight in April 2023?
In April 2023, NeuraLight introduced a new assessment tool for ALS based on abnormal eye movements, as reported by Medical Device Network.
What collaboration did NeuraLight announce in July 2022?
In July 2022, NeuraLight collaborated with NeuroSense Therapeutics to detect ALS using AI, as reported by CTech.
When did NeuraLight raise its Seed funding?
In October 2021, NeuraLight raised Seed funding, with MS&AD Ventures participating as a lead investor.

External links